Protagen, BioAnalytix, and GeneWerk unveil combined CRO business: ProtaGene

By Jane Byrne contact

- Last updated on GMT

© GettyImages/nirat
© GettyImages/nirat

Related tags: CRO, cell and gene therapies, Biologics

Protagen, BioAnalytix, and GeneWerk this week announced their unified operations and re-brand as ProtaGene, a CRO partner for the biologics and cell and gene therapy developers, from discovery to commercialization.

Protagen Protein Services, a global analytic CRO and expert in protein science, and BioAnalytix, a US-based advanced analytics and data analysis firm, aligned in April 2019. GeneWerk, with capabilities in vector safety, integration site analysis, and bioinformatics, merged into the group in 2021.

ProtaGene is backed by private equity player, Ampersand Capital Partners.

Mary Bowen, senior director, strategic and digital marketing (BioAnalytix), told BioPharma-Reporter that the CRO’s capabilities are equally focused on the US and European markets.

The organization is targeting multiyear programs with large, leading, public, pharmaceutical, biotechnology, and cell and gene therapy companies.

Operating four sites across Europe and North America, the CRO says it has expertise in protein, vector, gene expression, and genetic analytics, and teams focused on CMC development challenges and regulatory strategy opportunities, among other capabilities.

Addressing developmental challenges

When asked about how the combined capabilities will address the challenges faced by biopharma companies and cell and gene therapy developers, Bowen said: “ProtaGene is an external collaborator who can provide ongoing expert analytical support and proper candidate assessments based on high-quality data, which is crucial throughout the various phases of development.”

Annette Deichmann, senior VP, cell and gene therapy at ProtaGene and the cofounder of GeneWerk, said its experience in gene analytics – especially integration site analysis, vector purity, vector copy numbers, and bioinformatics analysis for preclinical development and clinical trials – will support many innovators in taking breakthrough therapies to the clinic. 

Related news

Show more

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more